154 related articles for article (PubMed ID: 31492770)
1. Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy-Refractory Testicular Tumors.
Lian B; Zhang W; Wang T; Yang Q; Jia Z; Chen H; Wang L; Xu J; Wang W; Cao K; Gao X; Sun Y; Shao C; Liu Z; Li J
Oncologist; 2019 Dec; 24(12):e1437-e1442. PubMed ID: 31492770
[TBL] [Abstract][Full Text] [Related]
2. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
Wilson MA; Zhao F; Khare S; Roszik J; Woodman SE; D'Andrea K; Wubbenhorst B; Rimm DL; Kirkwood JM; Kluger HM; Schuchter LM; Lee SJ; Flaherty KT; Nathanson KL
Clin Cancer Res; 2016 Jan; 22(2):374-82. PubMed ID: 26307133
[TBL] [Abstract][Full Text] [Related]
3. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Beyer J; Jonas U; Kanz L
World J Urol; 1996; 14(6):354-9. PubMed ID: 8986035
[TBL] [Abstract][Full Text] [Related]
4. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
5. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
[TBL] [Abstract][Full Text] [Related]
6. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
Hauschild A; Agarwala SS; Trefzer U; Hogg D; Robert C; Hersey P; Eggermont A; Grabbe S; Gonzalez R; Gille J; Peschel C; Schadendorf D; Garbe C; O'Day S; Daud A; White JM; Xia C; Patel K; Kirkwood JM; Keilholz U
J Clin Oncol; 2009 Jun; 27(17):2823-30. PubMed ID: 19349552
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Beyer J; Metzner B; Ruther U; Harstrick A; Weissbach L; Kohrmann U; Verbeek W; Schmoll HJ
Ann Oncol; 1996 Jan; 7(1):31-4. PubMed ID: 9081388
[TBL] [Abstract][Full Text] [Related]
8. Recent strategies for the use of paclitaxel in the treatment of urological malignancies.
Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Kollmannsberger C; Beyer J; Jonas U; Kanz L
World J Urol; 1998; 16(2):155-62. PubMed ID: 12073232
[TBL] [Abstract][Full Text] [Related]
9. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.
Jamal R; Lapointe R; Cocolakis E; Thébault P; Kazemi S; Friedmann JE; Dionne J; Cailhier JF; Bélanger K; Ayoub JP; Le H; Lambert C; El-Hajjar J; van Kempen LC; Spatz A; Miller WH
J Immunother Cancer; 2017 Nov; 5(1):83. PubMed ID: 29157311
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311).
Ishikawa M; Nakamura K; Shibata T; Tanaka K; Kitagawa R; Kobayashi H; Yaegashi N;
Jpn J Clin Oncol; 2018 Dec; 48(12):1096-1100. PubMed ID: 30295796
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel in salvage therapy for germ cell tumors.
Motzer RJ
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
[TBL] [Abstract][Full Text] [Related]
13. Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors.
Chiorean EG; Perkins SM; Strother RM; Younger A; Funke JM; Shahda SG; Hahn NM; Sandrasegaran K; Jones DR; Skaar TC; Schneider BP; Sweeney CJ; Matei DE
Mol Cancer Ther; 2020 Oct; 19(10):2155-2162. PubMed ID: 32847973
[TBL] [Abstract][Full Text] [Related]
14. Complete Response of Metastatic Melanoma to Second Line Chemotherapy with Paclitaxel and Carboplatin - Case Report.
Tomić K; Tica Sedlar I; Berić Jozić G; Marijanović I; Lukić B; Miletić D; Puljić Ćuk A
Acta Med Acad; 2018 May; 47(1):82-87. PubMed ID: 29957974
[TBL] [Abstract][Full Text] [Related]
15. Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report.
Sokolova A; Chan O; Ullah W; Hamdani AA; Anwer F
J Med Case Rep; 2017 Apr; 11(1):100. PubMed ID: 28395668
[TBL] [Abstract][Full Text] [Related]
16. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
17. Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report.
Ruzich JC; Ciesla MC; Clark JI
Head Neck; 2002 Apr; 24(4):406-10. PubMed ID: 11933184
[TBL] [Abstract][Full Text] [Related]
18. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
19. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Hainsworth JD; Thompson DS; Bismayer JA; Gian VG; Merritt WM; Whorf RC; Finney LH; Dudley BS
Cancer Med; 2015 May; 4(5):673-81. PubMed ID: 25556916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
